Liu Xinyu, Kifle Meron Tsegay, Xie Hongxin, Xu Liexi, Luo Maoling, Li Yangyi, Huang Zhengrong, Gong Yan, Wu Yuzhou, Xie Conghua
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China.
Nanomaterials (Basel). 2022 Sep 10;12(18):3138. doi: 10.3390/nano12183138.
Radiotherapy (RT) is currently considered as an essential treatment for non-small cell lung cancer (NSCLC); it can induce cell death directly and indirectly via promoting systemic immune responses. However, there still exist obstacles that affect the efficacy of RT such as tumor hypoxia and immunosuppressive tumor microenvironment (TME). Herein, we report that the biomineralized manganese oxide nanoparticles (Bio-MnO NPs) prepared by mild enzymatic reaction could be a promising candidate to synergistically enhance RT and RT-induced immune responses by relieving tumor hypoxia and activating cGAS-STING pathway. Bio-MnO NPs could convert endogenic HO to O and catalyze the generation of reactive oxygen species so as to sensitize the radiosensitivity of NSCLC cells. Meanwhile, the release of Mn into the TME significantly enhanced the cGAS-STING activity to activate radio-immune responses, boosting immunogenic cell death and increasing cytotoxic T cell infiltration. Collectively, this work presents the great promise of TME reversal with Bio-MnO NPs to collaborate RT-induced antitumor immune responses in NSCLC.
放射治疗(RT)目前被认为是非小细胞肺癌(NSCLC)的一种重要治疗方法;它可通过促进全身免疫反应直接和间接诱导细胞死亡。然而,仍然存在影响放疗疗效的障碍,如肿瘤缺氧和免疫抑制性肿瘤微环境(TME)。在此,我们报告通过温和酶促反应制备的生物矿化氧化锰纳米颗粒(Bio-MnO NPs)可能是一种有前景的候选物,可通过缓解肿瘤缺氧和激活cGAS-STING途径协同增强放疗及放疗诱导的免疫反应。Bio-MnO NPs可将内源性HO转化为O并催化活性氧的产生,从而使NSCLC细胞的放射敏感性增加。同时,Mn释放到肿瘤微环境中显著增强了cGAS-STING活性以激活放射免疫反应,促进免疫原性细胞死亡并增加细胞毒性T细胞浸润。总的来说,这项工作展示了利用Bio-MnO NPs逆转肿瘤微环境以协同放疗诱导NSCLC抗肿瘤免疫反应的巨大前景。